Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells

被引:0
作者
Vasiliki Panagiotakopoulou
Dina Ivanyuk
Silvia De Cicco
Wadood Haq
Aleksandra Arsić
Cong Yu
Daria Messelodi
Marvin Oldrati
David C. Schöndorf
Maria-Jose Perez
Ruggiero Pio Cassatella
Meike Jakobi
Nicole Schneiderhan-Marra
Thomas Gasser
Ivana Nikić-Spiegel
Michela Deleidi
机构
[1] German Center for Neurodegenerative Diseases (DZNE),Department of Neurodegenerative Diseases
[2] Hertie-Institute for Clinical Brain Research,Centre for Ophthalmology, Institute for Ophthalmic Research University of Tübingen
[3] University of Tübingen,Werner Reichardt Centre for Integrative Neuroscience
[4] University of Tübingen,undefined
[5] University of Tübingen,undefined
[6] NMI Natural and Medical Sciences Institute at the University of Tübingen,undefined
来源
Nature Communications | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Parkinson’s disease-associated kinase LRRK2 has been linked to IFN type II (IFN-γ) response in infections and to dopaminergic neuronal loss. However, whether and how LRRK2 synergizes with IFN-γ remains unclear. In this study, we employed dopaminergic neurons and microglia differentiated from patient-derived induced pluripotent stem cells carrying LRRK2 G2019S, the most common Parkinson’s disease-associated mutation. We show that IFN-γ enhances the LRRK2 G2019S-dependent negative regulation of AKT phosphorylation and NFAT activation, thereby increasing neuronal vulnerability to immune challenge. Mechanistically, LRRK2 G2019S suppresses NFAT translocation via calcium signaling and possibly through microtubule reorganization. In microglia, LRRK2 modulates cytokine production and the glycolytic switch in response to IFN-γ in an NFAT-independent manner. Activated LRRK2 G2019S microglia cause neurite shortening, indicating that LRRK2-driven immunological changes can be neurotoxic. We propose that synergistic LRRK2/IFN-γ activation serves as a potential link between inflammation and neurodegeneration in Parkinson’s disease.
引用
收藏
相关论文
共 122 条
[1]  
Hammond TR(2019)Immune signaling in neurodegeneration Immunity 50 955-974
[2]  
Marsh SE(2019)Genetic variability in response to amyloid beta deposition influences Alzheimer’s disease risk Brain Commun. 1 fcz022-192
[3]  
Stevens B(2020)Transcriptomic signatures of brain regional vulnerability to Parkinson’s disease Commun. Biol. 3 101-33
[4]  
Salih DA(2016)Type I/II interferon balance in the regulation of brain physiology and pathology Trends Immunol. 37 181-3337
[5]  
Keo A(2004)Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity Brain 127 21-97
[6]  
Deczkowska A(2007)Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons J. Neurosci. 27 3328-696
[7]  
Baruch K(2018)Parkinson’s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naive and drug-treated patients J. Neuroinflammation 15 94-1769
[8]  
Schwartz M(2007)p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the Parkinsonian brain Neurosci. Lett. 414 e115029-607
[9]  
Dale RC(2014)Differential co-expression between alpha-synuclein and IFN-gamma signaling genes across development and in Parkinson’s disease PLoS ONE 9 694-808
[10]  
Mount MP(2011)Interferon-gamma induces progressive nigrostriatal degeneration and basal ganglia calcification Nat. Neurosci. 14 1753-48